33 / 64
REUNIÓN 3
25
3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines
for the management of atrial fibrillation. The Task Force for the Management of
Atrial Fibrillation of the European Society of Cardiology (ESC). Developed with the
special contribution of the European Heart Rhythm Association (EHRA). Endorsed
by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart. J.
2010;31:2369-429.
4. Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation
Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines
2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and
flutter. Can J Cardiol. 2011;27:74-90.
5. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic
stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial
Fibrillation cohort study. Eur Heart J. 2012;33:1500-10.
6. Eikelboom JW,Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk
of bleeding with 2 doses of dabigatran compared with warfarin in older and younger
patients with atrial fibrillation: an analysis of the randomized evaluation of long-term
anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-72.
7. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF
Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J
Med. 2011;365:883-91.
8. Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. Efficacy and
safety of apixaban compared with warfarin according to patient risk of stroke and of
bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Lancet. 2012;380:1749-58.
9. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M,
Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L.
Efficacy and safety of apixaban compared with warfarin according to age for stroke
prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J.
2014;35:1864-72.
10. Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al; ATRIA
Study Investigators. Impact of proteinuria and glomerular filtration rate on risk of
thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial
fibrillation (ATRIA) study. Circulation. 2009;119:1363-9.